Patients with GBMs typically have a significantly short median survival time of approximately 15 months.24 BEV, which functions as a VEGF-A-targeting angiogenesis inhibitor and a modulator of tumor-induced immunosuppression, inhibits blood vessel growth and normalizes the tumor environment, thereby enhancing the effectiveness of chemotherapy.25,26 In patients with rHGGs, the efficacy and low toxicity of BEV have been confirmed.27 However, the therapeutic partners, treatment protocol, and treatment schedule of bevacizumab remain uncertain. This evidence concerns the gene VEGFA and neoplasm.